Pharmacolog is granted patent in the United States
Pressrelease in Swedish
Pharmacolog has been granted a patent in the United States regarding method and technique for adaptive dosage during intravenous drug treatments. In May 2016, the company received a positive review report on its PCT application and then applied for patents in the US, China and Europe.
The granted patent relates to method and technique for so-called adaptive dosage associated with intravenous treatments in health care, where careful dosage over time is crucial for successful patient recovery. For example, during treatment with chemotherapy or intravenous antibiotics. Today, there are no opportunities for such individualized dose regulation. The patent opens for a new and very excitin...
Aktieägarna i Pharmacolog i Uppsala AB (publ), org.nr 556723-6418 (”Bolaget”), kallas härmed till extra bolagsstämma onsdagen den 25 april 2018 kl. 16:00 i Advokatfirman Lindahls lokaler på Vaksalagatan 10, Uppsala.
Aktieägare som önskar delta vid bolagsstämman skall:
dels vara införd i den av Euroclear Sweden AB förda aktieboken torsdagen den 19 april 2018, och
dels anmäla sin avsikt att närvara senast fredagen den 20 april 2018 per post på adress Pharmacolog i Uppsala AB (publ), Ekeby Bruk A9, 752 75 Uppsala, eller per e-post till firstname.lastname@example.org.
Vid anmälan bör uppges aktieägarens namn, person- eller organisationsnummer (eller motsvarande), aktieinnehav, adress, telefonnummer...
The evaluation carried out at two hospitals in New York has now been completed with very good results. The evaluation lasted two months in the framework of a so-called Drug Diversion program. The hospital will during the summer initiate a formal procurement process of equipment.
Late in 2017, the Company signed an agreement with a reputable hospital chain in New York to evaluate DrugLog for Drug Diversion at two of the organization’s hospitals. The evaluation conducted by the hospital has shown that DrugLog can very well be used to control drug-based intravenous drugs within the framework of a Drug Diversion program. Drug Diversion means that the hospital controls that narcotic drugs used during surg...
Pharmacolog introduces ReVal ™ at EAHP in Gothenburg
At the European Conference EAHP, which takes place in Göteborg 21-23 March, Pharmacolog will introduce ReVal ™. ReVal ™ is a system to facilitate the reconstitution of medication in pediatric care. The system is based on the prototype developed with Astrid Lindgren’s children’s hospital with contributions from Vinnova.
At the annual conference of the European Association of Hospital Pharmacists (EAHP), Pharmacolog will for the first time show ReVal™. ReVal™ is a system that facilitates nursing staff in pediatric care to prepare drugs. The system uses validated instructions stored in the ePed national database and offers appropriate methods for quality assurance of the prepared drug prior to bei...
Pharmacolog has entered into an agreement with B. Braun Medical S.A Spain concerning exclusive distribution of DrugLog® on the Spanish market. The agreement also considers the future integration of DrugLog® with one of the company’s software Oncology technologies.
Braun Medical S.A. Spain is a company within the B. Braun Group engaged, among other activities, in the product development in the field of Injectable Drug Delivery. The area includes developing new solutions for managing the entire process of chemotherapy with cytotoxic drugs, from prescription to patient infusion. The agreement signed between Pharmacolog and B. Braun Medical Spain means that B. Braun acts as an exclusive distributor of Dr...
Aktieägarna i Pharmacolog i Uppsala AB (publ), org.nr 556723-6418 (”Bolaget”), kallas härmed till årsstämma torsdagen den 15 mars 2018 kl. 16.00 i Advokatfirman Lindahls lokaler på Vaksalagatan 10, Uppsala.
Aktieägare som önskar delta vid årsstämman skall:
– dels vara införd i den av Euroclear Sweden AB förda aktieboken onsdagen den 9 mars 2018, och
– dels anmäla sin avsikt att närvara senast kl. 16.00 fredagen den 12 mars 2018 per post på adress Pharmacolog i Uppsala AB (publ), Ekeby Bruk A9, 752 75 Uppsala, eller per e-post till email@example.com.
Vid anmälan bör uppges aktieägarens namn, person- eller organisationsnummer (eller motsvarande), aktieinnehav, adress,...
Continued negotiations with international MedTech Group
In a press release published September 6 2017, the Company announced that it had signed a letter of intent with a major MedTech Group about entering into a long-term cooperation. The goal was to have an agreement signed before the end of 2017, but the schedule has shifted slightly.
The letter of intent meant that the parties were working to establish a formal partnership agreement on the integration of DrugLog® technology into a newly developed system for effective handling of chemotherapy drugs at hospital pharmacies and healthcare wards. Work on establishing a formal agreement is in progress but the schedule has shifted slightly, and the goal is to have the agreement clear during the first quarter.
Extended collaboration with Uppsala University regarding dosage of antibiotics
Pharmacolog AB enters a new research and development cooperation with researchers from Uppsala University regarding methods for determining antibiotic concentration in the blood. The agreement is a direct continuation of the agreement signed in spring 2017, which runs until the end of the year.
The project carried out to date has been very successful and has shown that Pharmacolog’s technology can detect very small concentrations of antibiotics in blood. The parties have therefore decided to continue the cooperation with purpose to develop a clinical prototype for patient-related control of antibiotic levels in blood by 2018.
Hans Dahlin, Research Director and Founder, comments: “It is very ple...
The study conducted at the University Hospital in Lille with DrugLog in order to control drug preparations carried out in the operating room has now been completed. A total of 22 different drugs were checked and the result indicated an error rate in the drug preparations of 6.9%.
The study, conducted during the summer, was part of a doctoral thesis and the results were presented in connection with the dissertation at the Pharmacy Department earlier this fall. Of the 232 analyzes analyzed, it was found that 6.9% had a concentration beyond the tolerance level. According to the study, the cost of an error medication is about 4,000 €, which means that DrugLog control in these cases potentially resulted in a sa...
DrugLog® will be evaluated by a hospital chain in New York
Pharmacolog and one of New York’s most reputable hospital chains have signed an agreement that DrugLog® should be evaluated at two of the organization’s hospitals for use in a Drug Diversion program. The hospital chain pays for the evaluation scheduled to start in December and is expected to be completed in the first quarter of 2018.
Theft of narcotic intravenous drugs in healthcare is an growing problem. In the US, the authorities have initiated various preventive actions as the abuse of opiates reaches alarming levels. Since DrugLog can identify such drugs and also see if they have been manipulated in any way, DrugLog is a useful tool to prevent this development. The interest in using DrugLog...